SinoMab BioScience Ltd

SinoMab BioScience Ltd, or SinoMab, is a Hong Kong based clinical-phase biotech company. It was established in 2001 and is headquartered in Pak Shek Kok, Hong Kong. This company operates in various locations comprising Mainland China, the Cayman Islands, and Hong Kong.

Known as a biopharmaceutical company, SinoMab takes part in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. It usually focuses on the development of new and high-value recombinant therapeutic proteins for treating different life-threatening and hindering diseases in human. Its leading product is SM03, a first-in-target anti-CD22 mAb, which is not only in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), but also in a variety of clinical stages for other immunological diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL).

In addition to that, SinoMab also pay attention to make progress SN1011, a Bruton's tyrosine kinase inhibitor. This is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage include SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA.

Founded: 2001

Headquarters: HK Science Park, Pak Shek Kok,, HK

Website: https://www.sinomab.com/